Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ginger D Constantine

Showing results (11-20 of 50) with videos related to

Pageof 5
Sort By:
American Journal of Obstetrics and Gynecology|December 27, 2008
A double-blind, randomly assigned, placebo-controlled study of desvenlafaxine efficacy and safety for the treatment of vasomotor symptoms associated with menopauseDavid F Archer, Larry Seidman, Ginger D Constantine, et al.
American Journal of Obstetrics and Gynecology|January 27, 2009
Desvenlafaxine for the treatment of vasomotor symptoms associated with menopause: a double-blind, randomized, placebo-controlled trial of efficacy and safetyDavid F Archer, Caroline M Dupont, Ginger D Constantine, et al.
Menopause (New York, N.Y.)|August 3, 2020
17β-estradiol/progesterone in a single, oral, softgel capsule (TX-001HR) significantly increased the number of vasomotor symptom-free days in the REPLENISH trialAndrew M Kaunitz, Diana Bitner, Ginger D Constantine, et al.
Menopause (New York, N.Y.)|June 24, 2009
Relief of vasomotor symptoms with the tissue-selective estrogen complex containing bazedoxifene/conjugated estrogens: a randomized, controlled trialJoAnn V Pinkerton, Wulf H Utian, Ginger D Constantine, et al.
Menopause (New York, N.Y.)|November 26, 2014
Effects of ospemifene on the female reproductive and urinary tracts: translation from preclinical models into clinical evidenceDavid F Archer, Bruce R Carr, JoAnn V Pinkerton, et al.
Menopause (New York, N.Y.)|March 20, 2019
Endometrial safety of low-dose vaginal estrogens in menopausal women: a systematic evidence reviewGinger D Constantine, Shelli Graham, Kate Lapane, et al.
Menopause (New York, N.Y.)|January 3, 2019
Relationship between vasomotor symptom improvements and quality of life and sleep outcomes in menopausal women treated with oral, combined 17β-estradiol/progesteroneSebastian Mirkin, Shelli Graham, Dennis A Revicki, et al.
Fertility and Sterility|July 31, 2007
Occurrence of menses or pregnancy after cessation of a continuous oral contraceptiveAnne R Davis, Robin Kroll, Barbara Soltes, et al.
Menopause (New York, N.Y.)|July 13, 2016
Ospemifene's effect on vasomotor symptoms: a post hoc analysis of phase 2 and 3 clinical dataGinger D Constantine, David F Archer, Ricki Pollycove, et al.
Post Reproductive Health|February 21, 2016
Behaviours and attitudes influencing treatment decisions for menopausal symptoms in five European countriesGinger D Constantine, Shelli Graham, Cathy Clerinx, et al.
Pageof 5

Showing results (11-20 of 50) with videos related to

Sort By:
Pageof 5
American Journal of Obstetrics and Gynecology|December 27, 2008
A double-blind, randomly assigned, placebo-controlled study of desvenlafaxine efficacy and safety for the treatment of vasomotor symptoms associated with menopauseDavid F Archer, Larry Seidman, Ginger D Constantine, et al.
American Journal of Obstetrics and Gynecology|January 27, 2009
Desvenlafaxine for the treatment of vasomotor symptoms associated with menopause: a double-blind, randomized, placebo-controlled trial of efficacy and safetyDavid F Archer, Caroline M Dupont, Ginger D Constantine, et al.
Menopause (New York, N.Y.)|August 3, 2020
17β-estradiol/progesterone in a single, oral, softgel capsule (TX-001HR) significantly increased the number of vasomotor symptom-free days in the REPLENISH trialAndrew M Kaunitz, Diana Bitner, Ginger D Constantine, et al.
Menopause (New York, N.Y.)|June 24, 2009
Relief of vasomotor symptoms with the tissue-selective estrogen complex containing bazedoxifene/conjugated estrogens: a randomized, controlled trialJoAnn V Pinkerton, Wulf H Utian, Ginger D Constantine, et al.
Menopause (New York, N.Y.)|November 26, 2014
Effects of ospemifene on the female reproductive and urinary tracts: translation from preclinical models into clinical evidenceDavid F Archer, Bruce R Carr, JoAnn V Pinkerton, et al.
Menopause (New York, N.Y.)|March 20, 2019
Endometrial safety of low-dose vaginal estrogens in menopausal women: a systematic evidence reviewGinger D Constantine, Shelli Graham, Kate Lapane, et al.
Menopause (New York, N.Y.)|January 3, 2019
Relationship between vasomotor symptom improvements and quality of life and sleep outcomes in menopausal women treated with oral, combined 17β-estradiol/progesteroneSebastian Mirkin, Shelli Graham, Dennis A Revicki, et al.
Fertility and Sterility|July 31, 2007
Occurrence of menses or pregnancy after cessation of a continuous oral contraceptiveAnne R Davis, Robin Kroll, Barbara Soltes, et al.
Menopause (New York, N.Y.)|July 13, 2016
Ospemifene's effect on vasomotor symptoms: a post hoc analysis of phase 2 and 3 clinical dataGinger D Constantine, David F Archer, Ricki Pollycove, et al.
Post Reproductive Health|February 21, 2016
Behaviours and attitudes influencing treatment decisions for menopausal symptoms in five European countriesGinger D Constantine, Shelli Graham, Cathy Clerinx, et al.
Pageof 5